(179 days)
Not Found
No
The summary describes an automated system for antimicrobial susceptibility testing based on miniaturized doubling dilution. It monitors growth and generates MIC values and interpretive categories. There is no mention of AI or ML in the intended use, device description, or performance studies. The evaluation compares performance to a reference method, not against an AI/ML model.
No
The device is described as a "laboratory aid in the determination of in vitro susceptibility to antimicrobial agents" and is used for "automated quantitative or qualitative susceptibility testing." It does not directly treat or prevent a disease; rather, it provides information that aids in determining the effectiveness of antimicrobial agents.
Yes
The VITEK® 2 Gram Negative Doxycycline is designed for antimicrobial susceptibility testing, providing a quantitative test intended for use as a "laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." This information directly points to its role in diagnosing the susceptibility of microorganisms to specific drugs, which is a diagnostic function.
No
The device description clearly states it involves physical AST cards and the VITEK® 2 and VITEK® 2 Compact Systems, which are hardware instruments used for filling, sealing, incubating, and reading the cards. This indicates a hardware component is integral to the device's function.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is a "laboratory aid in the determination of in vitro susceptibility to antimicrobial agents." "In vitro" means "in glass" or "in the lab," referring to tests performed outside of a living organism.
- Device Description: The device performs antimicrobial susceptibility testing on isolated colonies, which is a common in vitro diagnostic procedure.
- Performance Studies: The performance studies compare the device's results to a "CLSI broth microdilution reference method," which is a standard laboratory technique for determining antimicrobial susceptibility.
- Predicate Device: The predicate device listed (K103752 VITEK® 2 Gram Negative Imipenem) is also an IVD, indicating that this type of device falls under the IVD category.
The device is designed to be used in a laboratory setting to test samples (bacterial isolates) outside of the human body to provide information for diagnosis and treatment decisions. This aligns perfectly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
VITEK® 2 Gram Negative Doxycline is designed for antimicrobial susceptibility testing of Gramnegative bacilli. VITEK 2 Gram Negative Doxycycline is a quantitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Doxycycline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.
Active in vitro and in clinical infections
Acinetobacter species Enterobacter aerogenes Escherichia coli Klebsiella species Shigella species
The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 and VITEK® 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Streptococcus spp., S. pneumoniae, and clinically significant yeast.
Product codes (comma separated list FDA assigned to the subject device)
LON
Device Description
The antimicrobial presented in VITEK® 2 AST-GN Cards is in concentrations equivalent by efficacy to standard method concentrations in ug/mL. The VITEK® 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
The isolate to be tested is diluted to a standardized concentration in 0.45 - 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling and sealing operation. The VITEK® 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antimicrobial contained on the card.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
laboratory aid
Description of the training set, sample size, data source, and annotation protocol
An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 GN Doxycycline by comparing its performance with the CLSI broth microditution reference method incubated at 24 hrs.
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
VITEK® 2 GN Doxycycline demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued August 28, 2009.
The Premarket Notification (510[k]) presents data in support of VITEK® 2 GN Doxycycline. The data is representative of performance on both the VITEK® 2 and VITEK® 2 Compact instrument platforms. VITEK® 2 GN Doxycycline demonstrated acceptable performance of 97.6% overall Essential Agreement and 95.1% overall Category Agreement with the reference method. Reproducibility and Quality Control demonstrated acceptable results using both the VITEK 2 and VITEK 2 Compact instrument systems.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
97.6% overall Essential Agreement and 95.1% overall Category Agreement with the reference method.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
K12/546
Image /page/0/Picture/1 description: The image shows the logo for bioMerieux. The logo consists of the word "BIOMERIEUX" in a sans-serif font, with a stylized graphic above it. The graphic is a circle that is divided into two halves, with one half filled with horizontal lines and the other half left blank. A curved line runs vertically through the center of the circle and extends above and below it.
NOV 2 0 2012 1
510(k) SUMMARY
VITEK® 2 Gram Negative Doxycycline
510(k) Submission Information:
Submitter's Name: | bioMérieux, Inc. |
---|---|
Address: | 595 Anglum Road |
Hazelwood, MO 63042 | |
Contact Person: | Jennifer Chia-Hsuan Lin |
Regulatory Affairs Specialist
Phone Number:
Fax Number:
314-731-8689
314 -731-8639
May 24, 2012
B. Device Name:
Formal/Trade Name:
Date of Preparation:
Classification Name:
21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial
Common Name:
VITEK® 2 AST-GN Doxycycline
Susceptibility System Product Code LON
VITEK® 2 Gram Negative Doxycycline
C. Predicate Device:
VITEK® 2 Gram Negative Imipenem (K103752)
D. 510(k) Summary:
VITEK® 2 Gram Negative Doxycycline is designed for antimicrobial susceptibility testing of Gramnegative bacilli. VITEK 2 GN Doxycycline is a quantitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Doxycycline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.
Active in vitro and in clinical infections Acinetobacter species Enterobacter aerogenes Escherichia coli Klebsiella species Shigella species
The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 and VITEK 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Streptococcus spp., S. pneumoniae, and clinically significant yeast.
bioMérieux, Inc.
Phone: 314/731-8500 800/638-4835 595 Anglum Road, Hazelwood, Missouri 63042-2320, USA Fax: 314/731-8700 http://www.biomerieux-usa.com
1
The antimicrobial presented in VITEK® 2 AST-GN Cards is in concentrations equivalent by efficacy to standard method concentrations in ug/mL. The VITEK® 2 AST Cards are essentially miniaturized versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.
The isolate to be tested is diluted to a standardized concentration in 0.45 - 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling and sealing operation. The VITEK® 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antimicrobial contained on the card.
VITEK® 2 GN Doxycycline demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued August 28, 2009.
The Premarket Notification (510[k]) presents data in support of VITEK® 2 GN Doxycycline. An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 GN Doxycycline by comparing its performance with the CLSI broth microditution reference method incubated at 24 hrs. The data is representative of performance on both the VITEK® 2 and VITEK® 2 Compact instrument platforms. VITEK® 2 GN Doxycycline demonstrated acceptable performance of 97.6% overall Essential Agreement and 95.1% overall Category Agreement with the reference method. Reproducibility and Quality Control demonstrated acceptable results using both the VITEK 2 and VITEK 2 Compact instrument systems.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three curved shapes that resemble a human figure.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
bioMerieux. Inc. C/O Jennifer Chia-Hsuan Lin. Regulatory Affairs Specialist 595 Anglum Road Hazelwood MO 63042
NOV 2 0 2012
Re: K121546
VITEK®2 Gram Negative Doxycycline Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-term Incubation Cycle Antimicrobial Susceptibility System Regulatory Class: Class II Product Code: LON Dated: October 19, 2012 Received: October 22, 2012
Dear Ms. Lin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sally A. Hojvat
Sally A. Hojvat, M.Sc., Ph.D. Director
Division of Microbiology Devices
Office of In Vitro Diagnostics and Radiological Health
Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known):_ K12 1846 / S00 1
Device Name: VITEK® 2 Gram Negative Doxycycline (16 ug/mL)
Indications For Use:
VITEK® 2 Gram Negative Doxycline is designed for antimicrobial susceptibility testing of Gramnegative bacilli. VITEK 2 Gram Negative Doxycycline is a quantitative test intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Doxycycline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.
Active in vitro and in clinical infections
Acinetobacter species Enterobacter aerogenes Escherichia coli Klebsiella species Shigella species
The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., S. pneumoniae, and clinically significant yeast.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Jayart
Division Sign-Off
Division Sign-C
Office of In Vitro Diagnostic Device Evaluation and Safety
510(K) KIZ 1 244
Page 1 of 1